Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

a treatment associated with both short- and long-term toxicities.

ALL, the most common form of leukemia in children, is a fast-growing cancer of the white blood cells in which the bone marrow makes a large number of abnormal white blood cells that are unable to develop and fight infection. Important developments over the past 20 years have led to seminal insights about ALL in children, and today nearly 90 percent of children diagnosed with standard-risk ALL are cured. Some treatment regimens for standard-risk ALL include initial infusions of daunorubicin, a type of anthracycline. While effective, continual use of this therapy is associated with potential long-term heart damage, leading researchers to assess whether eliminating or reducing the dosage of daunorubicin during the initial one-month induction therapy period might provide the same level of efficacy as the standard treatment protocol with reduced long-term risk.

In order to assess the efficacy of ALL treatment without daunorubicin during induction therapy, a team of researchers from 20 centers across France and one center in Belgium initiated a multicenter Phase III clinical trial in which 1,128 pediatric patients with standard-risk B-cell ALL were randomized into two treatment arms. Arm A included 560 patients who received a standard dose of daunorubicin during induction therapy, while Arm B included 568 patients who did not receive initial therapy with daunorubicin. Both groups received doxorubicin during delayed intensification (last treatment phase before reaching maintenance) and a standard protocol of 24-month maintenance therapy from December 2000 to June 2010, during which five-year event-free survival (EFS) and overall survival (OS) were assessed.

For those patients treated with daunorubicin, the five-year EFS rate was 92.9 percent, compared to 93.3 percent in the non-daunorubicin arm. Overall survival rates were 97.2 percent and 98.2 percent in the daunorubicin and n
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Not getting the right amount ... a new study suggests. Those who sleep less ... per night may be more prone to developing the ... report. The study authors concluded that duration and quality ... patients with inflammatory bowel diseases. "Both short and ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
(Date:10/22/2014)... TX (PRWEB) October 22, 2014 On ... Criminal Minds featuring skin diseases both fictional and ... (CEHMDF), a nonprofit organization committed to advocacy and ... if CBS will take the opportunity to impart truth ... , There are many misconceptions about ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... Ebola cases in Dallas. But, mental health specialists say overblown ... President Barack Obama on Friday appointed an Ebola "czar" to ... two Dallas nurses who cared for a Liberian man who ... But the U.S. cases are miniscule in the context ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3
... A drug whose clinical benefit in treating multiple sclerosis was ... Food and Drug Administration on January 22 and is now ... is the first therapy for multiple sclerosis that can be ... to treat impaired walking, a debilitating symptom of the disease ...
... ... renewed its multi year relationship with Seventh Generation, the leading global brand of green ... paper towels. , ... Hong Kong, China (April 1, 2010) – Serendipity House Limited, Hong Kong’s leading provider ...
... ... a new survey of U.S. healthcare organizations suggests that while organizations are updating their ... ... the healthcare industry prepares for a major shift to electronic health records (EHRs) over ...
... ... Techniques Are Impacting the Face of the Senior Care Industry , ... Newport Beach, Calif. (PRWEB) April 5, ... on how elder care marketers grow their businesses. The Elder Care Marketing Industry Report, ...
... discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has ... of conflicting data concerning XMRV, standardized diagnostic testing is ... and to determine whether it plays a role in ... the April issue of Urology is a ...
... Research on antibodies may aid vaccine development , MONDAY, April ... insight into how the body fights off HIV, a finding ... the virus, which causes AIDS. , At the moment, there,s ... develop a vaccine. HIV remains an extremely stubborn enemy. , ...
Cached Medicine News:Health News:Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center 2Health News:Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center 3Health News:Serendipity House Limited, the Leading Provider of Natural and Organic Products in Hong Kong, Renews Multi-year Relationship with Seventh Generation 2Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 2Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 3Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 4Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 5Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 6Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 7Health News:New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population 2Health News:New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population 3Health News:New investigation supports correlation between XMRV and prostate cancer 2Health News:Scientists Find Clues to How the Body Fights Off HIV 2
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... LA VERNE, Calif. , Oct. 22, 2014 ... emergency readiness products, has developed APLS ® ... bag that minimizes the spread of bacteria and ... APLS Body Guard Bio features a ... and finished edges that create a leak-proof inner ...
(Date:10/22/2014)... , Oct. 22, 2014  With a ... animal health medications, a Global Pharmaceutical and Biotech ... serialization technology and turnkey solution to protect their ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... that was serialized and aggregated by the Xyntek ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... 31 United,Therapeutics Corporation (Nasdaq: UTHR ) ... that they will release the results of their,TRIUMPH-1 ... of treprostinil,in pulmonary arterial hypertension (PAH) before market ... will expand its previously scheduled conference,call on November ...
... WASHINGTON, Oct. 31 American Meat Institute,Foundation Vice ... a response to the World Cancer Research Fund ... be available at the National Press,Club following WCRF,s ... Institute (AMI) is the nation,s oldest and largest,association ...
Cached Medicine Technology:Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: